PureTech Provides End of Year Report on Key Progress Across Wholly Owned Programs and Founded Entities

Author's Avatar
Dec 16, 2021

PureTech+Health+plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2021, including some updates that were not previously reported.